PetMeds® (PETS) Q4 2026: Revenue Decline Continues — Disappointing Quarter for Shareholders

PetMed Express, Inc. (NASDAQ: PETS) reported its fourth quarter and fiscal year 2026 financial results, revealing a significant decline in revenue and a net loss, which raises concerns for shareholders.

Key Financial Highlights

• Fourth Quarter Results:
  • Net Sales: $42.8 million, down from $50.8 million in the prior year, a decrease of 15.6%.
  • Net Loss: $4.1 million, or $(0.19) per diluted share, compared to a net loss of $11.6 million, or $(0.56) per diluted share in the prior year.
  • Adjusted EBITDA: $(2.8) million, compared to $(1.9) million in the prior year.
• Full Year Results:
  • Net Sales: $179.0 million, down from $227.0 million in the prior year, a decrease of 21.1%.
  • Net Loss: $57.3 million, or $(2.74) per diluted share, compared to a net loss of $6.3 million, or $(0.30) per diluted share in the prior year.
  • Adjusted EBITDA: $(15.4) million, compared to $0.7 million for the prior year.

Analyst View

This quarter is disappointing for shareholders, primarily due to the continued decline in net sales and the substantial net loss. The decrease in revenue, particularly driven by a decline in prescription medication sales, indicates ongoing challenges in the company's core business. While the reduction in net loss from the previous year is a positive sign, it is overshadowed by the overall financial performance, which reflects a deteriorating business environment.

The company's efforts to stabilize its operations and reduce costs are commendable, but the significant drop in sales raises questions about its ability to regain market share and profitability. The reported goodwill impairment charge of $26.7 million in the first quarter of fiscal 2026 further complicates the financial landscape, highlighting deeper issues within the company.

Additional Insights

• Cost Management: The decrease in general and administrative expenses and the absence of a prior-year trade name impairment charge contributed to a lower net loss. However, these factors were not sufficient to offset the impact of declining sales.
• Cash Position: The company ended the fiscal year with cash and cash equivalents of $21.4 million, a significant decrease from $54.7 million in the prior year, indicating potential liquidity concerns moving forward.
• Dividend and Share Buyback: The company paid dividends of $21, down from $181 in the previous year, reflecting a cautious approach to cash management amid financial struggles.

Forward Catalyst

Investors should closely monitor PetMeds' strategic initiatives aimed at improving customer retention and expanding its market footprint through B2B relationships and white-label pharmacy fulfillment services. The company's ability to execute on these plans will be critical in the upcoming quarters. Additionally, any developments regarding unsolicited acquisition proposals could also impact the stock's performance and investor sentiment.

In summary, while there are some positive signs in terms of cost management, the overall financial results for Q4 2026 and the full fiscal year indicate a challenging environment for PetMeds, necessitating careful observation by investors.

Note: All amounts are in thousands.

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF (LOSS) INCOME

(In thousands, except for share and per share amounts) (Unaudited)

Three Months Ended March 31, 2026	2025	Year Ended March 31, 2026	2025
Net sales $42,817	$50,760	$179,021	$226,972
Cost of sales $28,875	$35,564	$126,679	$157,835

Disclaimer

The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.